- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01679314
Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment
A Prospective, Single Site, Randomized, Controlled, Parallel Group Study in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Stage III and IV Using AlphaCore or Sham (Control, Not Active) as a Prophylactic Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PERFORMANCE AND SAFETY VARIABLES:
The primary efficacy endpoint for this study is the total Chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) score change from baseline to the 8 week follow-up period comparing the two device groups.
Secondary efficacy endpoints will be the mean difference from baseline to the 8 week follow-up for the following assessments: Medical Research Council (MRC) dyspnoea scale, 6 minutes walking test and Forced Expiratory Volume in one second (FEV1)
Safety Variables:
Each subject will be assessed throughout the study for Adverse Events and at the last visit (4 months) subjects will undergo another physical examination including vital signs and blood pressure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oder
-
Schwedt, Oder, Germany, D-16303
- Praxis fur Pneumologie am Asklepios Klinikum Uckermark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 40-75 years
- Diagnosed Chronic obstructive pulmonary disease(COPD) stage III and IV according to Global Initiative for chronic obstructive lung disease (GOLD) guideline
- Forced expiratory volume in one second (FEV 1) < 50%
- Forced expiratory volume in one second (FEV1/Forced expiratory vital capacity (FVC) < 70%
- Signed informed consent form
Exclusion Criteria:
- Participation in other clinical trials (drug or medical device) 30 days prior to start of this study
- Subject is unable to comply with the procedures if the protocol for the study or any other reason judged by the Investigator that could interfere with the study assessment or follow-up
- Has an abscess or other infection or lesion (including lymphadenopathy) at the AlphaCore® treatment site.
- Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- Has a history of carotid endarterectomy or vascular neck surgery on the right side.
- Right side or bilateral vagotomy
- Has a recent or repeated history of syncope.
- Has a recent or repeated history of seizures.
- Pregnant or breast feeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active AlphaCore device
AlphaCore active stimulation treatment
|
Each study group will go under the same treatment regimen and assessments.
|
Sham Comparator: Sham AlphaCore device
AlphaCore sham device
|
Each study group will go under the same treatment regimen and assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores (Quality of Life and Symptoms) Changes Within a Treatment Period and Comparison Between the Two Groups
Time Frame: 8 weeks
|
Chronic obstructive pulmonary disease Assessment Test (CAT) scores (Quality of life and symptoms) changes within a treatment period and comparison between the two groups.
Eight (8) questions.
The scale is rated from 0 to 5, min = 0, max = 5.
Low rates = better, high rates = worse.
Mean change in the period 8 weeks versus baseline.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Borg Dyspnoea Scores
Time Frame: Baseline vs 8 weeks
|
Borg dyspnoea scale (Physical activity test): 0 - 11 (Not at all effected - Extremely effected) The result show the change between the the treatment groups from baseline to week 8
|
Baseline vs 8 weeks
|
Change 6 Minutes Walking Test
Time Frame: Baseline vs 8 weeks
|
Six minutes walking test: Measure distance (meter) after 6 minutes walk.
Change from Baseline between treatment groups
|
Baseline vs 8 weeks
|
Change in Forced Expiratory Volume (FEV1)
Time Frame: Baseline vs 8 weeks
|
Forced Expiratory Volume (FEV1): Maximum volume that can be exhaled in the first second - after maximum inhalation. Change from baseline to week 8 between treatment groups |
Baseline vs 8 weeks
|
Change in EuroQol, 5 Questions and 3 Levels (EQ5D-3L)
Time Frame: Baseline vs 8 weeks
|
The EQ-5D-3L (EuroQoL 5 questions and 3 answering levels) during the run-in period will be compared with the EQ-5D-3L during the treatment period. And treatment period will be compared to open label. Rating of questions Level 1 no problems Level 2 some problems Level 3 Significant problems Worst case is 15 points and best case is 5 points using index |
Baseline vs 8 weeks
|
Number of Subjects With Adverse Events (AE)
Time Frame: Throughout the course of the study (baseline to the 4 month follow-up visit)
|
All AEs including but not limited to events reported by the subject or reported in response to an open question by the Clinical Investigator or member of this team, which fall into any of the above definitions must be recorded as an AE in the Case Report Form (CRF) and should include the following information.
|
Throughout the course of the study (baseline to the 4 month follow-up visit)
|
Change in Change in EuroQol, 5 Questions and 3 Levels (EQ-5D-3L), Visual Analogue Scale (VAS)
Time Frame: Baseline vs 8 weeks
|
Visual analogue scale (VAS) 0-100 where 0 is the worst imaginable health state and 100 the best imaginable health state
|
Baseline vs 8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matthias John, MD, Praxis fur Pneumologie am Asklepios Klinikum Uckermark
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on AlphaCore device
-
ElectroCore INCWithdrawn
-
ElectroCore INCTerminatedChronic Obstructive Pulmonary DiseaseCanada
-
University Hospital, AntwerpCompleted
-
ElectroCore INCTerminated
-
ElectroCore INCCompletedAsthmaUnited States
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg
-
Cala Health, Inc.Not yet recruiting
-
International Agency for Research on CancerUniversity of North Carolina Global Project Zambia; Liger Medical LlcCompleted